Mechanism of Competitive Inhibition
The process is based on structural analogy. The inhibitor ($I$) is very similar in structure to the substrate ($S$), making it complementary to the binding pockets (anchoring sites) of the enzyme's active site ($E$).
Direct competition arises between the substrate and the inhibitor for the same site on the enzyme. Two scenarios are possible:
- Normal reaction: The enzyme interacts with the substrate. An enzyme-substrate complex ($ES$) is formed, chemical conversion occurs at the catalytic site, and the reaction products ($P$) and free enzyme are subsequently released.
- Inhibition: The enzyme binds the inhibitor, resulting in an inactive enzyme-inhibitor complex ($EI$). The inhibitor physically blocks the substrate's access to the catalytic site, preventing product formation.
Characteristics and Kinetics
The main hallmark of competitive inhibition is its reversibility. The inhibitor is held within the active site by weak non-covalent bonds and is easily displaced when conditions change, without irreversibly destroying or altering the enzyme's structure.
The effect of the inhibitor depends directly on the substrate concentration. Significantly increasing the substrate concentration allows it to outcompete the inhibitor for the active sites. The probability of forming the productive $ES$ complex becomes much higher than forming the inactive $EI$ complex, thereby overcoming the inhibition.
From the perspective of Michaelis-Menten kinetics, this manifests as follows:
- Maximum velocity ($V_{max}$): Remains unchanged. At a sufficiently high (excess) substrate concentration, the enzyme still achieves its maximum throughput.
- Michaelis constant ($K_m$): Increases. The apparent affinity of the enzyme for the substrate is reduced. Achieving half of the maximum reaction velocity now requires a much higher substrate concentration than in the absence of the inhibitor.
Equilibrium Equations
In competitive inhibition, two competing binding processes occur in parallel within the system:
- Formation of the enzyme-substrate complex followed by catalysis:
$E + S \leftrightarrow ES \rightarrow E + P$
- Formation of the dead-end enzyme-inhibitor complex:
$E + I \leftrightarrow EI$
The $EI$ complex is incapable of further transformations and yields no product.
Clinical Significance
The principles of competitive inhibition are widely applied in pharmacology and the treatment of various pathologies.
Treatment of Pancreatic Disorders In acute pancreatitis and pancreatic necrosis, dangerous release of the active proteolytic enzyme trypsin into the blood and surrounding tissues occurs. This triggers autodigestion of the organ. To halt this destructive process, patients are administered peptide trypsin inhibitors (e.g., aprotinin). By binding to the enzyme, they block its activity.
Use of Pseudosubstrates Some competitive inhibitors act as pseudosubstrates (antimetabolites). They occupy the active site, and the enzyme may even catalyze the reaction, but the resulting synthesized product has a defective, "incorrect" structure. Such compounds completely lack normal functional activity. A classic example of this mechanism is the action of sulfonamide antibacterial drugs.